AstraZeneca CEO Pascal Soriot said it’s time for the U.S. to start paying more reasonable prices for new drugs, which are closer to what other wealthy countries pay, in a rare stance in an industry ...

AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

That’s how long it took from the time AstraZeneca CEO Pascal Soriot greeted Virginia Governor Glenn Youngkin in his London ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 billion in manufacturing.

British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States by 2030 amid US leader ...

AstraZeneca share price held steady this week after the company published strong financial results on Tuesday.

AstraZeneca adjusts its U.S. strategy by proposing drug price cuts and expanding local production in response to pressure ...

With the threat of tariffs looming for medicines imported to the United States, AstraZeneca has unveiled a plan to invest $50 ...